Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cerliponase alfa - BioMarin Pharmaceutical

Next Previous
Drug Profile

Cerliponase alfa - BioMarin Pharmaceutical

Alternative Names: BMN 190; BRINEURA; Brineura; recombinant human tripeptidyl peptidase-1; rhTPP1

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioMarin Pharmaceutical
  • Class Enzymes; Peptide hydrolases; Recombinant proteins
  • Mechanism of Action Tripeptidyl peptidase 1 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuronal ceroid lipofuscinosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Neuronal ceroid lipofuscinosis

Most Recent Events

  • 20 Apr 2022 BioMarin Pharmaceutical completes a phase II trial in Neuronal ceroid lipofuscinosis (In adolescents, In children) in USA, Germany, Italy and United Kingdom (Intracerebroventricular) (NCT02678689) (EudraCT2015-000891-85)
  • 31 Dec 2020 BioMarin Pharmaceutical has patent protection for Cerliponase alpha in USA and European union
  • 10 Dec 2020 BioMarin Pharmaceutical completed a phase-II trials in Neuronal ceroid lipofuscinosis (In children, In adolescents) in Germany, Italy, USA and United Kingdom (Intracerebral) (NCT02485899)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top